News Pulmocide raises $30m for inhaled anti-infectives A UK biotech company has raised $30 million to fund development of its treatments for respiratory infections.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
